Business Context and Reporting Period
Company: InfuSystem Holdings, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: April 2, 2024
Reporting Period: The filing addresses a delinquency regarding the Annual Report on Form 10-K for the fiscal year ended December 31, 2023.
Key Financial Metrics
This filing is a notice of delisting risk and does not contain specific financial performance data. The text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Delinquency Details
The Company received notice from NYSE Regulation on April 2, 2024, stating it is not in compliance with continued listing standards due to the failure to timely file its Form 10-K for the year ended December 31, 2023. The report was due on April 1, 2024.
Reason for Delay: The Company requires additional time to evaluate potential accounting errors related to:
- The classification of certain expenses included in general and administrative costs that should have been included in cost of sales.
- The adoption and ongoing application of Accounting Standards Update No. 2016-02, Leases (Topic 842/ASC 842).
Outlook, Risks, and Contingencies
Cure Periods: The Company has an initial six-month cure period from the date of the filing delinquency to file the delinquent report. The Exchange may grant an additional six-month cure period at its sole discretion.
Delisting Risk: If the Company fails to file the report during the cure periods, suspension and delisting procedures may commence. The Exchange reserves the right to truncate cure periods or immediately commence delisting if it deems continued listing inadvisable.
Management Commentary: The Company intends to regain compliance with the Exchange's continued listing standards, though there is no assurance this will be achieved.
Investor Verification Checklist
- Verify the status of the Form 10-K for the year ended December 31, 2023, and whether it has been filed with the SEC.
- Monitor communications from NYSE American regarding the status of the cure period and any potential delisting actions.
- Review future filings for details on the reclassification of expenses from general and administrative costs to cost of sales.
- Assess the impact of the ASC 842 lease accounting adjustments on the Company's financial position once the 10-K is filed.